MariTide's MARITIME trial programme
MariTide is an investigational antibody-peptide medicine, also called maridebart cafraglutide. Amgen’s November 3 update describes several ongoing Phase 3 studies, including a switching trial. Monthly or less frequent treatment is a research objective; the update is not an announcement of an approved alternative to weekly medicines. 1
What makes MariTide different?
The published Phase 2 abstract describes a molecule combining GLP-1 receptor activation with GIP receptor blockade. Both directions matter: a medicine acting on a receptor is not necessarily activating it. Its peptide-antibody construction also distinguishes MariTide from a simple list of individual peptide ingredients. 3
Amgen’s current program spans weight management, cardiovascular outcomes, heart failure and sleep apnea. These studies ask different questions in different populations. A result from one program should not be used as if it answered every other trial’s question. 1
What is the MARITIME-SWITCH study testing?
ClinicalTrials.gov describes a randomized Phase 3 study comparing two MariTide schedules after prior GLP-1 treatment. Its estimated enrollment is 300, with body-weight change at week 68 as the primary outcome. Secondary measures include how much previous weight reduction is maintained, drug concentrations and adverse events. 2
The registry snapshot checked on November 6 was recruiting and last updated October 23. Its two listed experimental arms both receive MariTide. This is an important distinction from a trial that randomly assigns participants to continue their previous medicine as an active comparison group. 2
| Question | Evidence to check |
|---|---|
| Who is switching? | Amgen describes people previously receiving weekly semaglutide or tirzepatide. |
| Which schedules? | The company describes eight-week or quarterly schedules in SWITCH. |
| When is the main weight outcome measured? | The registry specifies week 68. |
What did the earlier Phase 2 trial show?
The 2025 randomized study included 592 participants in separate obesity cohorts with and without type 2 diabetes. In the cohort without diabetes, average weight reductions ranged from 12.3% to 16.2% across MariTide groups versus 2.5% with placebo at week 52, using the treatment-policy estimand. Those are earlier Phase 2 findings, not new MARITIME results. 3
Gastrointestinal adverse events were common in that study. The abstract reports fewer such events with dose escalation and lower starting doses. A longer interval between administrations does not, by itself, establish better tolerability or fewer adverse effects. 3
How should readers compare monthly and weekly headlines?
Start with the trial population, comparator, follow-up length and analysis method. A percentage from a placebo-controlled study cannot establish superiority over another medicine studied elsewhere. A switching study also begins with people who have already received treatment, so its starting point differs from an initial weight-loss trial. Each comparison needs to be read against its own protocol and starting population.
The useful next evidence will be completed trial results showing both maintenance of weight reduction and adverse outcomes. Until those findings and a regulatory decision are available, the proposed schedules belong in a development timeline, not a personal switching plan. 1
Scope for European readers
This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.